CIMUC: Chemotherapy following Immune checkpoints inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).

• DOI: 10.1200/jco.2022.40.6_suppl.492
• Publication Date: 2022-02-16T21:35:25Z
• Authors: Lucie Meynard; Derek Dinart; Aude Flechon; Carolina Saldana; Felix Lefort; Gwenaelle Gravis; Antoine Thiery-Vu...; Mathilde Cancel; Elodie Coquan; Sylvain Ladoire; Denis Maillet; Frederic Rolland; Elouen Boughalem; Sophie Martin; Mathieu Laramas; Laurence Crouzet; Baptiste Abbar; Sabrina Falkowski; Damien Pouessel; Guilhem Roubaud
• Keywords: Clinical endpoint; Metastatic Urothelial Carcinoma

492 Background: Immune checkpoints inhibitors (ICIs) have recently changed therapeutic landscape of la/mUC. Recent studies suggested an improvement response to salvage chemotherapy (CT) after ICIs in several cancer types including urothelial carcinoma. We assumed that efficacy CT rechallenge may be improved compared second-line without previous patients (pts) with Methods: CIMUC is a French multicentric retrospective study all pts la/mUC initiating second or third-line from January 1 st 2015 June 30th 2020. Two groups were defined: group (G1) treated ICIs; 2 (G2) third line ICIs. Primary endpoint was objective rate (ORR: proportion complete partial response, according RECIST 1.1 criteria) G2 versus G1. Secondary endpoints progression-free survival (PFS), defined as time initiation disease progression death any cause, and toxicities. This supported by the Genito Urinary Group (GETUG). Results: 553 included. Baseline characteristics are summarized Table. ORRs 31% (95%CI [26.5-35.5]) 29.2% [21.9-36.6]) respectively G1 G2, statistically significant difference (p=0.617), even adjustment for Bellmunt risk factors (p=0.3214). In subgroups analysis, no ORR observed type (platinum taxanes), duration (DOR) first-platinum-based (< 12 months ≥ months) FGFR-status. did not identify predictive factor OR multivariate analysis. Median PFS 4.6 [3.88; 5.06]) 4.86 [4.11; 5.45]), G2. Grade 3/4 hematologic toxicity occurred 35% 22.4%, Conclusions: While superior G1, derive comparable benefit further treatment terms PFS. Despite limits inherent study, represents one largest this setting.[Table: see text]